Results 71 to 80 of about 8,174 (197)

A hepatitis C-vírus-bázispolimorfizmus jelentősége a kezelésben [PDF]

, 2015
Absztrakt A krónikus C-vírus hepatitis kezelése az elmúlt huszonöt évben igen jelentős fejlődésen ment keresztül.
Tornai, István
core   +1 more source

Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1

Терапевтический архив, 2017
Aim. To identify predictors for the high efficiency of short-term interferon-containing antiviral therapy (AVT) using direct-acting antivirals (DAAs) in patients with chronic hepatitis C (CHC) virus (HCV) type 1 (CHC-1). Materials and methods. A total of
K Yu Kokina, A O Bueverov, P O Bogomolov, M V Matsievich   +3 more
doaj   +1 more source

A hepatitis C-vírus-fertőzés és kezelésének költségvonzata [PDF]

, 2015
Absztrakt A hepatitis C-vírus-fertőzés a Föld lakosságának 2–3%-át érinti és a betegséghez társuló egyéni következmények mellett igen jelentős össztársadalmi gazdasági problémát jelent.
Hunyady, Béla, Makara, Mihály
core   +1 more source

Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals

GMS Ophthalmology Cases, 2016
We report a patient with a bilateral optic anterior ischemic neuropathy as an extrahepatic complication of a chronic hepatitis C (HCV) infection. The patient presented with a bilateral visual acuity loss and bilateral optic disc oedema.
Prud’homme, Sylvie, Nevens, Frederik, Casteels, Ingele   +2 more
doaj   +1 more source

New perspectives for preventing hepatitis C virus liver graft infection [PDF]

, 2016
publisher: Elsevier articletitle: New perspectives for preventing hepatitis C virus liver graft infection journaltitle: The Lancet Infectious Diseases articlelink: http://dx.doi.org/10.1016/S1473-3099(16)00120-1 content_type: article copyright: © 2016 ...
Abdelmalek, Adam, Akazawa, Andre, Audrey Coilly, Bandiera, Bankwitz, Baumert, Benedicto, Berenguer, Berenguer, Berenguer, Berenguer, Bizollon, Blasco, Brown, Bzowej, Carrion, Carrion, Carrion, Chalasani, Charlton, Charlton, Charlton, Charlton, Chung, Ciesek, Coilly, Coilly, Coilly, Colpitts, Colpitts, Crespo, Curry, Curry, Daniel J Felmlee, Davis, de Jong, Denniston, Desombere, Deuffic-Burban, Didier Samuel, Fafi-Kremer, Faisal, Fauvelle, Feld, Felmlee, Firpi, Fofana, Fofana, Fofana, Forman, Forns, Forns, Foster, Foster, Fukasawa, Fukuhara, Gambato, Gane, Gane, Gerold, Guedj, Haberstroh, Haid, He, Helle, Hopcraft, Janssen, Ji, Jiang, Keck, Khan, Kim, Kong, Kugelmas, Kwo, Kwo, Lanford, Law, Leroy, Lin, Lupberger, Mailly, Manns, Manns, Marino, Martin, Martin, Masaki, Mazzaferro, Meuleman, Meuleman, Meuleman, Munoz, O'Shea, Ojo, Ouwerkerk-Mahadevan, Owsianka, Pawlotsky, Perin, Picciotto, Ploss, Ploss, Poordad, Prieto, Pungpapong, Raymond T Chung, Reddy, Roche, Rowe, Rowe, Sainz, Shergill, St Vincent, Sugawara, Sulkowski, Takaki, Terrault, Thomas F Baumert, Toso, Uprichard, Van Der Ree, Vanwolleghem, Veldt, Vercauteren, Vercauteren, von Hahn, Walter, Wang, Watt, Wedemeyer, Welker, Xiao, Xiao, Xirouchakis, Yamashita, Zahid, Zeisel, Zeisel, Zhang, Zhang, Zhu, Zona   +143 more
core   +4 more sources

Efficacy and safety of daclatasvir-containing regimens in the treatment of chronic hepatitis C patients in Damietta

Al-Azhar Assiut Medical Journal, 2020
Background Chronic hepatitis C virus infection is one of the most important health problems in Egypt. Since November 2015, generic sofosbuvir (SOF) with daclatasvir (DCV)±ribavirin (RBV) became the standard treatment in all National Committee for Control
Alaa Eldeen M Hashim, Samy Zaky, Magdy Z Alghannam, Sabry A Ibraheem, Fathiya M El-Raey, Ahmed Abdelaziz   +5 more
doaj   +1 more source

Reassessment of genotype 1 hepatitis c virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment [PDF]

, 2014
The accuracy of LiPA 2.0 for hepatitis C virus 1 (HCV-1) subtype classification was analyzed. LiPA 2.0 genotype results from 101 HCV-1-infected patients were compared to genotype findings determined by direct core sequencing.
Di Lello, Federico Alejandro, Guelfo, Javier R., Macias, Juan, Mancebo, María, Merchante, Nicolás, Mira José Antonio, Neukam, Karin, Nuñez Torres, Rocío, Pineda, Juan A., Real. Luis M.   +9 more
core   +1 more source

Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivirals (DAA) in patients treated with Atezolizumab plus Bevacizumab (AtezoBev).
Leonardo Stella, Giuseppe Cabibbo, Ciro Celsa, Roberta Ciccia, Alba Sparacino, Fabio Piscaglia, Francesco Tovoli, Andrea Arleo, Bernardo Stefanini, Massimo Iavarone, Roberta D'Ambrosio, Lucia Cerrito, Maria Pallozzi, Francesco Santopaolo, Fabio Marra, Claudia Campani, Chiara Mazzarelli, Raffaella Viganò, Raffaella Tortora, Alessio Aghemo, Stella De Nicola, Tiziana Pressiani, Lorenza Rimassa, Sherrie Bhoori, Salvatore Corallo, Laura Maiocchi, Andrea Martini, Caterina Soldà, Francesco Paolo Russo, Antonio Gasbarrini, Francesca Romana Ponziani   +30 more
wiley   +1 more source

Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine

, 2015
Worldwide, hepatitis C virus (HCV) is a common infection. Due to new antiviral approaches and the approval of direct-acting antiviral agents (DAA), HCV therapy has become more comfortable. Nevertheless, there are special patient groups, in whom treatment
Heinzow, H. (Hauke), Hüsing, A.K.E.P. (Anna), Kabar, I. (Iyad), Schmidt, H. (Hartmut)   +3 more
core   +2 more sources

Dysregulated Cholesterol Metabolism and Its Impact on the Tumour Immune Response in Colorectal Cancer

Journal of Cellular and Molecular Medicine, Volume 29, Issue 15, August 2025.
ABSTRACT Colorectal cancer (CRC) ranks among the primary causes of cancer deaths worldwide. Cholesterol metabolism, tightly regulated through biosynthesis, uptake, efflux and conversion, plays a crucial role in CRC development and progression. Dysregulated cholesterol metabolism in cancer cells alters the tumour microenvironment (TME), promoting tumour
Chunyu Zhang, Zhiwei Miao, Yan Xu, Xingchao Zhu, Tongguo Shi   +4 more
wiley   +1 more source